Back

Direct detection of humoral marker corelates of COVID-19, glycated HSA and hyperglycosylated IgG3, by MALDI-ToF mass spectrometry.

Iles, R. K.; Iles, J. K.; Zmuidinaite, R.; Gardiner, A.; Lacey, J.; Harding, S.; Heeney, J. L.; Baxendale, D. H.

2021-07-10 infectious diseases
10.1101/2021.07.08.21260186
Show abstract

The prefusion Spike protein of SARS-CoV2 binds advanced glycation end product (AGE) glycated human serum albumin (HSA) and a higher mass, hyperglycosylated/glycated, IgG3, as determined by matrix assisted laser desorption mass spectrometry (MALDI-ToF MS). We set out to investigate if the total blood plasma of patients who had recovered from acute respiratory distress as a result of COVID-19, contained more glycated HSA and higher mass (glycosylated/glycated) IgG3 than those with only clinically mild or asymptomatic infections. A direct dilution and disulphide bond reduction method was development and applied to plasma samples from SARS-CoV2 seronegative (N = 30) and seropositive (N = 31) healthcare workers and 38 convalescent plasma samples from patients who had been admitted with acute respiratory distress syndrome (ARDS) associated with COVID-19. Patients recovering from COVID-19 ARDS had significantly higher mass, AGE-glycated HSA and higher mass IgG3 levels. This would indicate that increased levels and/or ratios of hyper-glycosylation (probably terminal sialic acid) IgG3 and AGE glycated HSA may be predisposition markers for development of ARDS as a result of COVID-19 infection. Furthermore, rapid direct analysis of plasma samples by MALDI-ToF MS for such humoral immune correlates of COVID-19 presents a feasible screening technology for the most at risk; regardless of age or known health conditions. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/21260186v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@12bfa69org.highwire.dtl.DTLVardef@45344forg.highwire.dtl.DTLVardef@16d4f7forg.highwire.dtl.DTLVardef@17e5c34_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 46%
11.1%
2
Frontiers in Immunology
based on 140 papers
Top 0.5%
11.0%
3
Scientific Reports
based on 701 papers
Top 24%
7.5%
4
International Journal of Molecular Sciences
based on 39 papers
Top 0.2%
5.0%
5
Life Science Alliance
based on 11 papers
Top 0.1%
4.5%
6
Viruses
based on 79 papers
Top 1%
2.8%
7
The Journal of Immunology
based on 19 papers
Top 0.7%
2.4%
8
Frontiers in Medicine
based on 99 papers
Top 8%
2.4%
9
Analytical Chemistry
based on 15 papers
Top 0.5%
2.2%
10
eBioMedicine
based on 82 papers
Top 2%
1.8%
50% of probability mass above
11
Journal of Medical Virology
based on 95 papers
Top 5%
1.8%
12
iScience
based on 74 papers
Top 3%
1.8%
13
Biomedicines
based on 21 papers
Top 1%
1.8%
14
Journal of Virological Methods
based on 20 papers
Top 1%
1.6%
15
Nature Communications
based on 483 papers
Top 35%
1.3%
16
PLOS Pathogens
based on 35 papers
Top 1%
1.3%
17
Journal of Clinical Medicine
based on 77 papers
Top 13%
1.2%
18
eLife
based on 262 papers
Top 25%
1.2%
19
EMBO Molecular Medicine
based on 15 papers
Top 2%
1.2%
20
Emerging Microbes & Infections
based on 20 papers
Top 1%
0.8%
21
JCI Insight
based on 63 papers
Top 6%
0.8%
22
Nature Medicine
based on 88 papers
Top 16%
0.8%
23
Clinical & Translational Immunology
based on 14 papers
Top 1%
0.7%
24
Biosensors and Bioelectronics
based on 13 papers
Top 1%
0.7%
25
Frontiers in Cellular and Infection Microbiology
based on 22 papers
Top 5%
0.7%
26
Genomics, Proteomics & Bioinformatics
based on 10 papers
Top 2%
0.7%
27
EBioMedicine
based on 21 papers
Top 3%
0.7%
28
Diagnostics
based on 36 papers
Top 6%
0.7%
29
International Journal of Infectious Diseases
based on 115 papers
Top 20%
0.7%
30
Journal of Clinical Virology
based on 54 papers
Top 5%
0.7%